Li Zhu

机构：Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (United States), Biological E (India), National Clinical Research · ORCID：0000-0002-8804-4897

发表论文 54 篇 · 总被引 870 次 · h-index 15

代表论文

• Using Child‐Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model‐based Analysis (2020 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 被引 21)
• Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies (2024 · Clinical Cancer Research · 被引 16)
• Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs (2024 · Journal of Clinical Oncology · 被引 9)
• Optimization of tigecycline dosage regimen for different infections in the patients with hepatic or renal impairment (2020 · Journal of Chemotherapy · 被引 8)
• Cutaneous dysbiosis in girls with vulvar lichen sclerosus (2025 · Microbiology Spectrum · 被引 4)
• Pharmacokinetic and Exposure–Response Modeling Support Body Surface Area‐Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors (2025 · The Journal of Clinical Pharmacology · 被引 3)